Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of$ 0.78. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.54%. A quarter ago, it was expected that this company would post a loss of$ 0.81 per share when it actually produced earnings of $0.54, delivering a surprise of 166.67%.Over the last four quarters, the comp ...